Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans

Michael S Lipkowitz, Barry I Freedman, Carl D Langefeld, Mary E Comeau, Donald W Bowden, W H Linda Kao, Brad C Astor, Erwin P Bottinger, Sudha K Iyengar, Paul E Klotman, Richard G Freedman, Weijia Zhang, Rulan S Parekh, Michael J Choi, George W Nelson, Cheryl A Winkler, Jeffrey B Kopp, SK Investigators, Michael S Lipkowitz, Barry I Freedman, Carl D Langefeld, Mary E Comeau, Donald W Bowden, W H Linda Kao, Brad C Astor, Erwin P Bottinger, Sudha K Iyengar, Paul E Klotman, Richard G Freedman, Weijia Zhang, Rulan S Parekh, Michael J Choi, George W Nelson, Cheryl A Winkler, Jeffrey B Kopp, SK Investigators

Abstract

Despite intensive antihypertensive therapy there was a high incidence of renal end points in participants of the African American Study of Kidney Disease and Hypertension (AASK) cohort. To better understand this, coding variants in the apolipoprotein L1 (APOL1) and the nonmuscle myosin heavy chain 9 (MYH9) genes were evaluated for an association with hypertension-attributed nephropathy and clinical outcomes in a case-control study. Clinical data and DNA were available for 675 AASK participant cases and 618 African American non-nephropathy control individuals. APOL1 G1 and G2, and MYH9 E1 variants along with 44 ancestry informative markers, were genotyped with allele frequency differences between cases and controls analyzed by logistic regression multivariable models adjusting for ancestry, age, and gender. In recessive models, APOL1 risk variants were significantly associated with kidney disease in all cases compared to controls with an odds ratio of 2.57. In AASK cases with more advanced disease, such as a baseline urine protein to creatinine ratio over 0.6 g/g or a serum creatinine over 3 mg/dl during follow-up, the association was strengthened with odds ratios of 6.29 and 4.61, respectively. APOL1 risk variants were consistently associated with renal disease progression across medication classes and blood pressure targets. Thus, kidney disease in AASK participants was strongly associated with APOL1 renal risk variants.

Conflict of interest statement

No other author has a competing interest to declare.

References

    1. Kiberd BA, Clase CM. Cumulative risk for developing end-stage renal disease in the US population. J Am Soc Nephrol. 2002;13:1635–1644.
    1. U S Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
    1. Kao WH, Klag MJ, Meoni LA, Reich D, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40:1185–1192.
    1. Kopp JB, Smith MW, Nelson GW, Johnson RC, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40:1175–1184.
    1. Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009;75:736– 745.
    1. Genovese G, Friedman DJ, Ross MD, Lecordier L, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329:841–845.
    1. Tzur S, Rosset S, Shemer R, Yudkovsky G, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128:345–350.
    1. Cooke JN, Bostrom MA, Hicks PJ, Ng MC, et al. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant. 2012;27:1505–1511.
    1. O’Seaghdha CM, Parekh RS, Hwang SJ, Li M, et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet. 2011;20:2450–2456.
    1. Wright JT, Jr, Kusek JW, Toto RD, Lee JY, et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials. 1996;17:3S–16S.
    1. Appel LJ, Wright JT, Jr, Greene T, Agodoa LY, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–929.
    1. Fogo A, Breyer JA, Smith MC, Cleveland WH, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int. 1997;51:244– 252.
    1. Appel LJ, Wright JT, Jr, Greene T, Kusek JW, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008;168:832–839.
    1. Shulman NB, Ford CE, Hall WD, Blaufox MD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989;13:I80–93.
    1. Walker WG, Neaton JD, Cutler JA, Neuwirth R, et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA. 1992;268:3085–3091.
    1. Marcantoni C, Ma LJ, Federspiel C, Fogo AB. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 2002;62:172–180.
    1. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant. 2011;11:1025–1030.
    1. Wright JT, Jr, Bakris G, Greene T, Agodoa LY, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431.
    1. Chen Y, Lipkowitz MS, Salem RM, Fung MM, et al. Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. Am J Nephrol. 2010;32:23–30.
    1. Fung MM, Salem RM, Lipkowitz MS, Bhatnagar V, et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC) Nephrol Dial Transplant. 2012;27:197–205.
    1. Ashley-Koch AE, Okocha EC, Garrett ME, et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol. 2011;155:386–394.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する